The tumor microenvironment and immune responses in prostate cancer patients
The landscape of cancer treatment has been transformed over the past decade by the success of immune-targeting therapies. However, despite sipuleucel-T being the first-ever approved vaccine for cancer and the first immunotherapy licensed for prostate cancer in 2010, immunotherapy has since seen limi...
| Main Authors: | , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
BioScientifica
2021
|